Daniel JD - GeneDx Holdings Secretary
| WGSWW Stock | 0.26 0.02 8.33% |
Executive
Daniel JD is Secretary of GeneDx Holdings Corp
| Age | 43 |
| Address | North Tower, Stamford, CT, United States, 06902 |
| Phone | 888 729 1206 |
| Web | https://www.genedx.com |
GeneDx Holdings Management Efficiency
The company has return on total asset (ROA) of (0.032) % which means that it has lost $0.032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.221) %, meaning that it generated substantial loss on money invested by shareholders. GeneDx Holdings' management efficiency ratios could be used to measure how well GeneDx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2025. Return On Capital Employed is likely to drop to -0.07 in 2025. At this time, GeneDx Holdings' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 5.6 M in 2025, whereas Intangible Assets are likely to drop slightly above 138.1 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jason Ryan | GeneDx Holdings Corp | 50 | |
| Paul MD | GeneDx Holdings Corp | N/A | |
| Kevin CPA | GeneDx Holdings Corp | 44 | |
| Yang MD | Humacyte | 59 | |
| FACMG MD | GeneDx Holdings Corp | N/A | |
| Feras Hantash | GeneDx Holdings Corp | N/A | |
| Sabrina Dunbar | GeneDx Holdings Corp | N/A | |
| Jerry Conway | GeneDx Holdings Corp | N/A | |
| MBA JD | GeneDx Holdings Corp | N/A | |
| Karen Ponchner | GeneDx Holdings Corp | N/A | |
| William Scheessele | Humacyte | 53 | |
| SPHR GPHR | Humacyte | N/A | |
| Shamik MD | Humacyte | 52 | |
| Kevin Feeley | GeneDx Holdings Corp | 43 | |
| Harold Alterson | Humacyte | N/A | |
| Heidi JD | GeneDx Holdings Corp | 58 | |
| Melanie Duquette | GeneDx Holdings Corp | N/A | |
| Britt Johnson | GeneDx Holdings Corp | N/A | |
| Bryan Dechairo | GeneDx Holdings Corp | 51 | |
| Tricia Truehart | GeneDx Holdings Corp | N/A | |
| Sabrina Osborne | Humacyte | N/A | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.032 |
GeneDx Holdings Corp Leadership Team
Elected by the shareholders, the GeneDx Holdings' board of directors comprises two types of representatives: GeneDx Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneDx. The board's role is to monitor GeneDx Holdings' management team and ensure that shareholders' interests are well served. GeneDx Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneDx Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, Secretary | ||
| Heidi JD, Chief Officer | ||
| Britt Johnson, Head Affairs | ||
| Katherine Stueland, CEO President | ||
| Jami Biliboaca, Head Strategy | ||
| Eric Olivares, Chief Officer | ||
| Tricia Truehart, Head Relations | ||
| MBA JD, General Counsel | ||
| Bryan Dechairo, Chief Officer | ||
| FACMG MD, Chief Officer | ||
| Sabrina Dunbar, Chief Staff | ||
| Jerry Conway, Senior Access | ||
| Kevin Feeley, Chief Officer | ||
| Paul MD, Chief Officer | ||
| Melanie Duquette, Chief Officer | ||
| Jennifer Brendel, Chief Affairs | ||
| Feras Hantash, Senior Oncology | ||
| Kevin CPA, Chief Officer | ||
| Jason Ryan, Executive Board | ||
| Karen Ponchner, Senior Operations |
GeneDx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GeneDx Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.032 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | 0.11 % | ||||
| Number Of Shares Shorted | 6.28 K | ||||
| Revenue | 305.45 M | ||||
| Gross Profit | 194.45 M | ||||
| EBITDA | (23.21 M) | ||||
| Net Income | (52.29 M) | ||||
| Total Debt | 64.25 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.